Susquehanna International Group’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.26M | Sell |
384,400
-421,000
| -52% | -$4.01M | ﹤0.01% | 5109 |
|
|
2025
Q4 | $9.78M | Buy |
805,400
+627,400
| +352% | +$7.62M | ﹤0.01% | 3071 |
|
|
2025
Q3 | $2.08M | Buy |
178,000
+160,500
| +917% | +$1.92M | ﹤0.01% | 5706 |
|
|
2025
Q2 | $162K | Sell |
17,500
-13,100
| -43% | -$103K | ﹤0.01% | 11435 |
|
|
2025
Q1 | $224K | Sell |
30,600
-25,400
| -45% | -$195K | ﹤0.01% | 10704 |
|
|
2024
Q4 | $478K | Sell |
56,000
-24,100
| -30% | -$235K | ﹤0.01% | 8770 |
|
|
2024
Q3 | $697K | Sell |
80,100
-7,700
| -9% | -$63.5K | ﹤0.01% | 7670 |
|
|
2024
Q2 | $601K | Sell |
87,800
-237,400
| -73% | -$1.47M | ﹤0.01% | 7826 |
|
|
2024
Q1 | $2.96M | Buy |
325,200
+228,800
| +237% | +$1.62M | ﹤0.01% | 4548 |
|
|
2023
Q4 | $430K | Buy |
96,400
+49,700
| +106% | +$147K | ﹤0.01% | 9033 |
|
|
2023
Q3 | $147K | Sell |
46,700
-117,000
| -71% | -$479K | ﹤0.01% | 10561 |
|
|
2023
Q2 | $845K | Sell |
163,700
-44,300
| -21% | -$263K | ﹤0.01% | 7078 |
|
|
2023
Q1 | $1.1M | Buy |
208,000
+32,700
| +19% | +$155K | ﹤0.01% | 6565 |
|
|
2022
Q4 | $493K | Sell |
175,300
-103,200
| -37% | -$342K | ﹤0.01% | 7909 |
|
|
2022
Q3 | $1.16M | Buy |
278,500
+234,200
| +529% | +$1.18M | ﹤0.01% | 6266 |
|
|
2022
Q2 | $178K | Sell |
44,300
-123,100
| -74% | -$465K | ﹤0.01% | 10809 |
|
|
2022
Q1 | $829K | Sell |
167,400
-60,200
| -26% | -$334K | ﹤0.01% | 7623 |
|
|
2021
Q4 | $1.59M | Sell |
227,600
-343,800
| -60% | -$2.67M | ﹤0.01% | 6077 |
|
|
2021
Q3 | $5.71M | Buy |
571,400
+204,400
| +56% | +$2.3M | ﹤0.01% | 3713 |
|
|
2021
Q2 | $5.2M | Buy |
367,000
+95,800
| +35% | +$1.46M | ﹤0.01% | 3973 |
|
|
2021
Q1 | $4.45M | Buy |
271,200
+168,700
| +165% | +$3.25M | ﹤0.01% | 4141 |
|
|
2020
Q4 | $2.12M | Sell |
102,500
-103,800
| -50% | -$1.54M | ﹤0.01% | 4967 |
|
|
2020
Q3 | $1.57M | Sell |
206,300
-11,300
| -5% | -$93.8K | ﹤0.01% | 5087 |
|
|
2020
Q2 | $1.81M | Buy |
217,600
+140,500
| +182% | +$931K | ﹤0.01% | 4674 |
|
|
2020
Q1 | $382K | Buy |
77,100
+52,300
| +211% | +$258K | ﹤0.01% | 7500 |
|
|
2019
Q4 | $98K | Sell |
24,800
-10,700
| -30% | -$37.2K | ﹤0.01% | 9151 |
|
|
2019
Q3 | $108K | Sell |
35,500
-17,000
| -32% | -$76K | ﹤0.01% | 9530 |
|
|
2019
Q2 | $231K | Buy |
52,500
+35,200
| +203% | +$130K | ﹤0.01% | 8844 |
|
|
2019
Q1 | $69K | Sell |
17,300
-46,800
| -73% | -$188K | ﹤0.01% | 8391 |
|
|
2018
Q4 | $255K | Sell |
64,100
-23,900
| -27% | -$132K | ﹤0.01% | 7304 |
|
|
2018
Q3 | $605K | Buy |
88,000
+44,400
| +102% | +$279K | ﹤0.01% | 6181 |
|
|
2018
Q2 | $294K | Sell |
43,600
-37,200
| -46% | -$256K | ﹤0.01% | 7889 |
|
|
2018
Q1 | $526K | Buy |
80,800
+3,300
| +4% | +$18.6K | ﹤0.01% | 6533 |
|
|
2017
Q4 | $345K | Sell |
77,500
-36,200
| -32% | -$185K | ﹤0.01% | 7348 |
|
|
2017
Q3 | $703K | Buy |
113,700
+12,000
| +12% | +$77.3K | ﹤0.01% | 5928 |
|
|
2017
Q2 | $943K | Sell |
101,700
-17,800
| -15% | -$172K | ﹤0.01% | 5384 |
|
|
2017
Q1 | $1.11M | Buy |
119,500
+44,100
| +58% | +$367K | ﹤0.01% | 4906 |
|
|
2016
Q4 | $631K | Sell |
75,400
-31,000
| -29% | -$240K | ﹤0.01% | 6495 |
|
|
2016
Q3 | $731K | Buy |
106,400
+69,700
| +190% | +$425K | ﹤0.01% | 5379 |
|
|
2016
Q2 | $182K | Buy |
36,700
+22,600
| +160% | +$224K | ﹤0.01% | 7675 |
|
|
2016
Q1 | $136K | Buy |
+14,100
| New | +$107K | ﹤0.01% | 8273 |
|
|
2015
Q4 | – | Sell |
-50,600
| Closed | -$711K | – | 9794 |
|
|
2015
Q3 | $711K | Buy |
+50,600
| New | +$1.02M | ﹤0.01% | 6433 |
|
Other funds holding OCUL
DTC
ACA
SR
VA
VCM
Susquehanna International Group's OCUL Position: Q1 2026 in Review
Susquehanna International Group increased its Ocular Therapeutix (OCUL) stake by 1,315% in Q1 2026, buying an estimated $1.34M and bringing the position to 150,744 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #7272.
Susquehanna International Group first reported a position in OCUL in Q4 2015 and has held it in 35 quarters since. The position peaked at $16.6M in Q2 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.
- Susquehanna International Group held 150,744 shares of Ocular Therapeutix worth $1.28M as of Q1 2026.
- Susquehanna International Group bought 140,091 Ocular Therapeutix shares in Q1 2026, an estimated $1.34M.
- Ocular Therapeutix made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7272 holding.
- Susquehanna International Group first reported a position in Ocular Therapeutix in Q4 2015 and has held it in 35 quarters since.
- Susquehanna International Group's Ocular Therapeutix position peaked at $16.6M in Q2 2025.
- 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.